nodes	percent_of_prediction	percent_of_DWPC	metapath
Methadone—HTR3A—enteric nervous system—Crohn's disease	0.15	0.392	CbGeAlD
Methadone—HTR3A—myenteric nerve plexus—Crohn's disease	0.114	0.297	CbGeAlD
Methadone—CYP3A5—Sulfasalazine—Crohn's disease	0.0568	0.404	CbGbCtD
Methadone—CYP2C19—Prednisone—Crohn's disease	0.0366	0.26	CbGbCtD
Methadone—ABCB1—Prednisone—Crohn's disease	0.0295	0.21	CbGbCtD
Methadone—Muscle mass—Prednisone—Crohn's disease	0.0276	0.0662	CcSEcCtD
Methadone—CHRNA10—lymphoid tissue—Crohn's disease	0.0189	0.0491	CbGeAlD
Methadone—CYP3A4—Prednisone—Crohn's disease	0.0177	0.126	CbGbCtD
Methadone—Ache—Mesalazine—Crohn's disease	0.0153	0.0367	CcSEcCtD
Methadone—CYP2C18—mammalian vulva—Crohn's disease	0.0146	0.0381	CbGeAlD
Methadone—CYP2C18—digestive system—Crohn's disease	0.0128	0.0334	CbGeAlD
Methadone—Hypomagnesaemia—Mesalazine—Crohn's disease	0.0111	0.0267	CcSEcCtD
Methadone—CHRNA10—lymph node—Crohn's disease	0.0106	0.0277	CbGeAlD
Methadone—Abdominal cramps—Mesalazine—Crohn's disease	0.0105	0.0251	CcSEcCtD
Methadone—Lung disorder—Mesalazine—Crohn's disease	0.00997	0.0239	CcSEcCtD
Methadone—Withdrawal symptom—Prednisone—Crohn's disease	0.0091	0.0218	CcSEcCtD
Methadone—Intracranial pressure increased—Prednisone—Crohn's disease	0.00894	0.0215	CcSEcCtD
Methadone—Withdrawal syndrome—Prednisone—Crohn's disease	0.00894	0.0215	CcSEcCtD
Methadone—Rhinorrhoea—Mesalazine—Crohn's disease	0.00871	0.0209	CcSEcCtD
Methadone—HTR3A—digestive system—Crohn's disease	0.00863	0.0225	CbGeAlD
Methadone—Amenorrhoea—Mesalazine—Crohn's disease	0.00803	0.0193	CcSEcCtD
Methadone—Drug withdrawal syndrome—Prednisone—Crohn's disease	0.00761	0.0183	CcSEcCtD
Methadone—Osteoporosis—Prednisone—Crohn's disease	0.00666	0.016	CcSEcCtD
Methadone—Fracture—Prednisone—Crohn's disease	0.00642	0.0154	CcSEcCtD
Methadone—Multiple fractures—Prednisone—Crohn's disease	0.00642	0.0154	CcSEcCtD
Methadone—Disorientation—Mesalazine—Crohn's disease	0.00573	0.0137	CcSEcCtD
Methadone—Libido decreased—Mesalazine—Crohn's disease	0.00552	0.0133	CcSEcCtD
Methadone—CYP2C19—digestive system—Crohn's disease	0.00545	0.0142	CbGeAlD
Methadone—CYP2B6—skin of body—Crohn's disease	0.00534	0.0139	CbGeAlD
Methadone—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.00508	0.0122	CcSEcCtD
Methadone—Orthostatic hypotension—Mesalazine—Crohn's disease	0.00468	0.0112	CcSEcCtD
Methadone—Oedema—Mercaptopurine—Crohn's disease	0.00464	0.0111	CcSEcCtD
Methadone—Nasopharyngitis—Mesalazine—Crohn's disease	0.00458	0.011	CcSEcCtD
Methadone—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.00454	0.0109	CcSEcCtD
Methadone—CYP1A2—digestive system—Crohn's disease	0.00445	0.0116	CbGeAlD
Methadone—Anorexia—Mercaptopurine—Crohn's disease	0.00442	0.0106	CcSEcCtD
Methadone—CYP2B6—lymphoid tissue—Crohn's disease	0.00432	0.0113	CbGeAlD
Methadone—CYP3A5—digestive system—Crohn's disease	0.0043	0.0112	CbGeAlD
Methadone—CYP2B6—digestive system—Crohn's disease	0.00427	0.0111	CbGeAlD
Methadone—Amenorrhoea—Prednisone—Crohn's disease	0.00425	0.0102	CcSEcCtD
Methadone—CYP2C9—digestive system—Crohn's disease	0.00423	0.011	CbGeAlD
Methadone—Decreased appetite—Mercaptopurine—Crohn's disease	0.00403	0.00968	CcSEcCtD
Methadone—Weight increased—Mesalazine—Crohn's disease	0.00403	0.00967	CcSEcCtD
Methadone—Weight decreased—Mesalazine—Crohn's disease	0.00401	0.00962	CcSEcCtD
Methadone—CYP19A1—lymph node—Crohn's disease	0.0038	0.00989	CbGeAlD
Methadone—Sweating—Mesalazine—Crohn's disease	0.00378	0.00908	CcSEcCtD
Methadone—Body temperature increased—Mercaptopurine—Crohn's disease	0.00367	0.0088	CcSEcCtD
Methadone—Chills—Azathioprine—Crohn's disease	0.00349	0.00838	CcSEcCtD
Methadone—Arrhythmia—Azathioprine—Crohn's disease	0.00348	0.00834	CcSEcCtD
Methadone—Hypersensitivity—Mercaptopurine—Crohn's disease	0.00342	0.0082	CcSEcCtD
Methadone—Pulmonary oedema—Prednisone—Crohn's disease	0.00332	0.00798	CcSEcCtD
Methadone—CYP3A4—digestive system—Crohn's disease	0.00322	0.00839	CbGeAlD
Methadone—Euphoric mood—Prednisone—Crohn's disease	0.00321	0.0077	CcSEcCtD
Methadone—Chills—Mesalazine—Crohn's disease	0.00318	0.00763	CcSEcCtD
Methadone—Diarrhoea—Mercaptopurine—Crohn's disease	0.00317	0.00762	CcSEcCtD
Methadone—CYP2D6—digestive system—Crohn's disease	0.00317	0.00826	CbGeAlD
Methadone—Erythema—Mesalazine—Crohn's disease	0.00309	0.00741	CcSEcCtD
Methadone—ABCB1—epithelium—Crohn's disease	0.003	0.00781	CbGeAlD
Methadone—Muscle spasms—Mesalazine—Crohn's disease	0.00297	0.00712	CcSEcCtD
Methadone—Vomiting—Mercaptopurine—Crohn's disease	0.00295	0.00708	CcSEcCtD
Methadone—Rash—Mercaptopurine—Crohn's disease	0.00293	0.00702	CcSEcCtD
Methadone—Dermatitis—Mercaptopurine—Crohn's disease	0.00292	0.00701	CcSEcCtD
Methadone—Tremor—Mesalazine—Crohn's disease	0.00289	0.00694	CcSEcCtD
Methadone—Cardiac failure—Prednisone—Crohn's disease	0.00278	0.00667	CcSEcCtD
Methadone—Vertigo—Mesalazine—Crohn's disease	0.00277	0.00665	CcSEcCtD
Methadone—Syncope—Mesalazine—Crohn's disease	0.00277	0.00664	CcSEcCtD
Methadone—Nausea—Mercaptopurine—Crohn's disease	0.00276	0.00661	CcSEcCtD
Methadone—Palpitations—Mesalazine—Crohn's disease	0.00273	0.00654	CcSEcCtD
Methadone—Loss of consciousness—Mesalazine—Crohn's disease	0.00271	0.00651	CcSEcCtD
Methadone—Thrombocytopenia—Azathioprine—Crohn's disease	0.00271	0.0065	CcSEcCtD
Methadone—Anxiety—Mesalazine—Crohn's disease	0.00262	0.00628	CcSEcCtD
Methadone—ABCB1—mammalian vulva—Crohn's disease	0.0026	0.00677	CbGeAlD
Methadone—Irritability—Prednisone—Crohn's disease	0.00259	0.00621	CcSEcCtD
Methadone—Hypotension—Azathioprine—Crohn's disease	0.00258	0.0062	CcSEcCtD
Methadone—Cardiac arrest—Prednisone—Crohn's disease	0.00258	0.00619	CcSEcCtD
Methadone—Dry mouth—Mesalazine—Crohn's disease	0.00257	0.00617	CcSEcCtD
Methadone—Confusional state—Mesalazine—Crohn's disease	0.00254	0.00609	CcSEcCtD
Methadone—Anaphylactic shock—Mesalazine—Crohn's disease	0.00252	0.00604	CcSEcCtD
Methadone—Oedema—Mesalazine—Crohn's disease	0.00252	0.00604	CcSEcCtD
Methadone—Shock—Mesalazine—Crohn's disease	0.00248	0.00595	CcSEcCtD
Methadone—Hypokalaemia—Prednisone—Crohn's disease	0.00247	0.00592	CcSEcCtD
Methadone—Thrombocytopenia—Mesalazine—Crohn's disease	0.00247	0.00592	CcSEcCtD
Methadone—Tachycardia—Mesalazine—Crohn's disease	0.00246	0.0059	CcSEcCtD
Methadone—Hyperhidrosis—Mesalazine—Crohn's disease	0.00243	0.00584	CcSEcCtD
Methadone—Anorexia—Mesalazine—Crohn's disease	0.0024	0.00576	CcSEcCtD
Methadone—Hypotension—Mesalazine—Crohn's disease	0.00235	0.00565	CcSEcCtD
Methadone—ABCB1—lymphoid tissue—Crohn's disease	0.00231	0.00602	CbGeAlD
Methadone—ABCB1—digestive system—Crohn's disease	0.00228	0.00594	CbGeAlD
Methadone—Sweating increased—Prednisone—Crohn's disease	0.00228	0.00548	CcSEcCtD
Methadone—Feeling abnormal—Azathioprine—Crohn's disease	0.00228	0.00547	CcSEcCtD
Methadone—Insomnia—Mesalazine—Crohn's disease	0.00228	0.00547	CcSEcCtD
Methadone—Gastrointestinal pain—Azathioprine—Crohn's disease	0.00226	0.00543	CcSEcCtD
Methadone—Somnolence—Mesalazine—Crohn's disease	0.00224	0.00537	CcSEcCtD
Methadone—Decreased appetite—Mesalazine—Crohn's disease	0.00219	0.00525	CcSEcCtD
Methadone—Abdominal pain—Azathioprine—Crohn's disease	0.00219	0.00524	CcSEcCtD
Methadone—Body temperature increased—Azathioprine—Crohn's disease	0.00219	0.00524	CcSEcCtD
Methadone—Pain—Mesalazine—Crohn's disease	0.00215	0.00517	CcSEcCtD
Methadone—Constipation—Mesalazine—Crohn's disease	0.00215	0.00517	CcSEcCtD
Methadone—Weight increased—Prednisone—Crohn's disease	0.00213	0.00512	CcSEcCtD
Methadone—Weight decreased—Prednisone—Crohn's disease	0.00212	0.00509	CcSEcCtD
Methadone—Feeling abnormal—Mesalazine—Crohn's disease	0.00207	0.00498	CcSEcCtD
Methadone—Gastrointestinal pain—Mesalazine—Crohn's disease	0.00206	0.00494	CcSEcCtD
Methadone—Hypersensitivity—Azathioprine—Crohn's disease	0.00204	0.00489	CcSEcCtD
Methadone—Urticaria—Mesalazine—Crohn's disease	0.002	0.0048	CcSEcCtD
Methadone—Abdominal pain—Mesalazine—Crohn's disease	0.00199	0.00478	CcSEcCtD
Methadone—Body temperature increased—Mesalazine—Crohn's disease	0.00199	0.00478	CcSEcCtD
Methadone—Bradycardia—Prednisone—Crohn's disease	0.00191	0.00458	CcSEcCtD
Methadone—Diarrhoea—Azathioprine—Crohn's disease	0.00189	0.00454	CcSEcCtD
Methadone—Hallucination—Prednisone—Crohn's disease	0.00187	0.00448	CcSEcCtD
Methadone—Hypersensitivity—Mesalazine—Crohn's disease	0.00186	0.00445	CcSEcCtD
Methadone—Dizziness—Azathioprine—Crohn's disease	0.00183	0.00439	CcSEcCtD
Methadone—Asthenia—Mesalazine—Crohn's disease	0.00181	0.00434	CcSEcCtD
Methadone—Pruritus—Mesalazine—Crohn's disease	0.00178	0.00428	CcSEcCtD
Methadone—Vomiting—Azathioprine—Crohn's disease	0.00176	0.00422	CcSEcCtD
Methadone—Rash—Azathioprine—Crohn's disease	0.00174	0.00418	CcSEcCtD
Methadone—Dermatitis—Azathioprine—Crohn's disease	0.00174	0.00418	CcSEcCtD
Methadone—Flushing—Prednisone—Crohn's disease	0.00174	0.00418	CcSEcCtD
Methadone—Headache—Azathioprine—Crohn's disease	0.00173	0.00416	CcSEcCtD
Methadone—Diarrhoea—Mesalazine—Crohn's disease	0.00172	0.00414	CcSEcCtD
Methadone—Arrhythmia—Prednisone—Crohn's disease	0.00168	0.00402	CcSEcCtD
Methadone—Dizziness—Mesalazine—Crohn's disease	0.00167	0.004	CcSEcCtD
Methadone—Nausea—Azathioprine—Crohn's disease	0.00164	0.00394	CcSEcCtD
Methadone—Erythema—Prednisone—Crohn's disease	0.00163	0.00392	CcSEcCtD
Methadone—Vomiting—Mesalazine—Crohn's disease	0.0016	0.00384	CcSEcCtD
Methadone—Rash—Mesalazine—Crohn's disease	0.00159	0.00381	CcSEcCtD
Methadone—Dermatitis—Mesalazine—Crohn's disease	0.00159	0.00381	CcSEcCtD
Methadone—Headache—Mesalazine—Crohn's disease	0.00158	0.00379	CcSEcCtD
Methadone—Agitation—Prednisone—Crohn's disease	0.0015	0.0036	CcSEcCtD
Methadone—Nausea—Mesalazine—Crohn's disease	0.0015	0.00359	CcSEcCtD
Methadone—Vertigo—Prednisone—Crohn's disease	0.00147	0.00352	CcSEcCtD
Methadone—Syncope—Prednisone—Crohn's disease	0.00146	0.00351	CcSEcCtD
Methadone—Loss of consciousness—Prednisone—Crohn's disease	0.00143	0.00344	CcSEcCtD
Methadone—Convulsion—Prednisone—Crohn's disease	0.00141	0.00339	CcSEcCtD
Methadone—Anxiety—Prednisone—Crohn's disease	0.00138	0.00332	CcSEcCtD
Methadone—Anaphylactic shock—Prednisone—Crohn's disease	0.00133	0.0032	CcSEcCtD
Methadone—Oedema—Prednisone—Crohn's disease	0.00133	0.0032	CcSEcCtD
Methadone—Shock—Prednisone—Crohn's disease	0.00131	0.00315	CcSEcCtD
Methadone—ABCB1—lymph node—Crohn's disease	0.0013	0.00339	CbGeAlD
Methadone—Tachycardia—Prednisone—Crohn's disease	0.0013	0.00312	CcSEcCtD
Methadone—Hyperhidrosis—Prednisone—Crohn's disease	0.00129	0.00309	CcSEcCtD
Methadone—Anorexia—Prednisone—Crohn's disease	0.00127	0.00305	CcSEcCtD
Methadone—Insomnia—Prednisone—Crohn's disease	0.0012	0.00289	CcSEcCtD
Methadone—Decreased appetite—Prednisone—Crohn's disease	0.00116	0.00278	CcSEcCtD
Methadone—Constipation—Prednisone—Crohn's disease	0.00114	0.00273	CcSEcCtD
Methadone—Feeling abnormal—Prednisone—Crohn's disease	0.0011	0.00263	CcSEcCtD
Methadone—Gastrointestinal pain—Prednisone—Crohn's disease	0.00109	0.00261	CcSEcCtD
Methadone—Urticaria—Prednisone—Crohn's disease	0.00106	0.00254	CcSEcCtD
Methadone—Abdominal pain—Prednisone—Crohn's disease	0.00105	0.00253	CcSEcCtD
Methadone—Body temperature increased—Prednisone—Crohn's disease	0.00105	0.00253	CcSEcCtD
Methadone—Hypersensitivity—Prednisone—Crohn's disease	0.000981	0.00236	CcSEcCtD
Methadone—Asthenia—Prednisone—Crohn's disease	0.000956	0.00229	CcSEcCtD
Methadone—Pruritus—Prednisone—Crohn's disease	0.000943	0.00226	CcSEcCtD
Methadone—Diarrhoea—Prednisone—Crohn's disease	0.000911	0.00219	CcSEcCtD
Methadone—Dizziness—Prednisone—Crohn's disease	0.000881	0.00211	CcSEcCtD
Methadone—Vomiting—Prednisone—Crohn's disease	0.000847	0.00203	CcSEcCtD
Methadone—Rash—Prednisone—Crohn's disease	0.00084	0.00202	CcSEcCtD
Methadone—Dermatitis—Prednisone—Crohn's disease	0.000839	0.00201	CcSEcCtD
Methadone—Headache—Prednisone—Crohn's disease	0.000835	0.002	CcSEcCtD
Methadone—Nausea—Prednisone—Crohn's disease	0.000791	0.0019	CcSEcCtD
Methadone—Diphenhydramine—SLC22A5—Crohn's disease	0.000231	0.41	CrCbGaD
Methadone—Oxaprozin—PTGS2—Crohn's disease	0.0002	0.355	CrCbGaD
Methadone—Phenylbutazone—PTGS2—Crohn's disease	0.000132	0.235	CrCbGaD
Methadone—OPRK1—Signaling Pathways—MLN—Crohn's disease	0.000102	0.00175	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	0.000101	0.00174	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCR9—Crohn's disease	0.000101	0.00173	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CCR6—Crohn's disease	9.92e-05	0.0017	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—Crohn's disease	9.85e-05	0.00169	CbGpPWpGaD
Methadone—CYP3A4—Metapathway biotransformation—GPX4—Crohn's disease	9.71e-05	0.00167	CbGpPWpGaD
Methadone—OPRK1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	9.71e-05	0.00167	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	9.66e-05	0.00166	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—GPR65—Crohn's disease	9.37e-05	0.00161	CbGpPWpGaD
Methadone—OPRD1—G alpha (i) signalling events—CXCL8—Crohn's disease	9.34e-05	0.00161	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PLA2G4F—Crohn's disease	9.3e-05	0.0016	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TAGAP—Crohn's disease	9.29e-05	0.0016	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RSPO3—Crohn's disease	9.26e-05	0.00159	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	9.24e-05	0.00159	CbGpPWpGaD
Methadone—CYP1A2—Arachidonic acid metabolism—PTGS2—Crohn's disease	9.22e-05	0.00158	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Crohn's disease	9.17e-05	0.00158	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—ACKR2—Crohn's disease	9.06e-05	0.00156	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CCR6—Crohn's disease	9.01e-05	0.00155	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—Crohn's disease	8.92e-05	0.00153	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SEL1L—Crohn's disease	8.78e-05	0.00151	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—PTGER4—Crohn's disease	8.73e-05	0.0015	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CCR6—Crohn's disease	8.7e-05	0.00149	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	8.62e-05	0.00148	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—MLN—Crohn's disease	8.59e-05	0.00148	CbGpPWpGaD
Methadone—OPRM1—TCR Signaling Pathway—IL6—Crohn's disease	8.38e-05	0.00144	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IFNG—Crohn's disease	8.35e-05	0.00144	CbGpPWpGaD
Methadone—OPRM1—Peptide ligand-binding receptors—CXCL8—Crohn's disease	8.21e-05	0.00141	CbGpPWpGaD
Methadone—OPRK1—G alpha (i) signalling events—CXCL8—Crohn's disease	8.19e-05	0.00141	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RSPO3—Crohn's disease	8.12e-05	0.0014	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PLA2G4F—Crohn's disease	8.08e-05	0.00139	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—FADS1—Crohn's disease	8.05e-05	0.00138	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCR9—Crohn's disease	8.03e-05	0.00138	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—SLC22A5—Crohn's disease	8e-05	0.00137	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—SLC22A4—Crohn's disease	8e-05	0.00137	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—PTGER4—Crohn's disease	7.93e-05	0.00136	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—MTMR3—Crohn's disease	7.91e-05	0.00136	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4F—Crohn's disease	7.9e-05	0.00136	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CCR6—Crohn's disease	7.9e-05	0.00136	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	7.86e-05	0.00135	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TAGAP—Crohn's disease	7.85e-05	0.00135	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—CXCL8—Crohn's disease	7.77e-05	0.00133	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SEL1L—Crohn's disease	7.7e-05	0.00132	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—PTGER4—Crohn's disease	7.66e-05	0.00132	CbGpPWpGaD
Methadone—HTR3A—Transmembrane transport of small molecules—ALB—Crohn's disease	7.59e-05	0.0013	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—GPX4—Crohn's disease	7.54e-05	0.0013	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	7.52e-05	0.00129	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—GPR65—Crohn's disease	7.47e-05	0.00128	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—IL1B—Crohn's disease	7.45e-05	0.00128	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—IL3—Crohn's disease	7.44e-05	0.00128	CbGpPWpGaD
Methadone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	7.43e-05	0.00128	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CCR6—Crohn's disease	7.35e-05	0.00126	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—GCKR—Crohn's disease	7.28e-05	0.00125	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—RASGRP1—Crohn's disease	7.19e-05	0.00124	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	7.04e-05	0.00121	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCR9—Crohn's disease	7.04e-05	0.00121	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—PTGER4—Crohn's disease	6.95e-05	0.00119	CbGpPWpGaD
Methadone—OPRM1—G alpha (i) signalling events—CXCL8—Crohn's disease	6.92e-05	0.00119	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—MTMR3—Crohn's disease	6.87e-05	0.00118	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RSPO3—Crohn's disease	6.87e-05	0.00118	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL3—Crohn's disease	6.75e-05	0.00116	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—MTMR3—Crohn's disease	6.72e-05	0.00115	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.72e-05	0.00115	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CCR6—Crohn's disease	6.67e-05	0.00115	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Crohn's disease	6.65e-05	0.00114	CbGpPWpGaD
Methadone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Crohn's disease	6.65e-05	0.00114	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—GPR65—Crohn's disease	6.55e-05	0.00113	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—RASGRP1—Crohn's disease	6.53e-05	0.00112	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—IL3—Crohn's disease	6.52e-05	0.00112	CbGpPWpGaD
Methadone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	6.51e-05	0.00112	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SEL1L—Crohn's disease	6.51e-05	0.00112	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—PTGER4—Crohn's disease	6.47e-05	0.00111	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—RASGRP1—Crohn's disease	6.31e-05	0.00108	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	6.29e-05	0.00108	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—FADS1—Crohn's disease	6.16e-05	0.00106	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	6.12e-05	0.00105	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PLA2G4F—Crohn's disease	5.97e-05	0.00103	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCR9—Crohn's disease	5.95e-05	0.00102	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL3—Crohn's disease	5.92e-05	0.00102	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—PTGER4—Crohn's disease	5.88e-05	0.00101	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PLA2G4F—Crohn's disease	5.84e-05	0.001	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—GPX4—Crohn's disease	5.77e-05	0.000992	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	5.73e-05	0.000985	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—RASGRP1—Crohn's disease	5.73e-05	0.000984	CbGpPWpGaD
Methadone—OPRD1—GPCR ligand binding—CXCL8—Crohn's disease	5.66e-05	0.000972	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—GCKR—Crohn's disease	5.64e-05	0.000969	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—GCKR—Crohn's disease	5.57e-05	0.000958	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—GPR65—Crohn's disease	5.53e-05	0.000951	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—IL3—Crohn's disease	5.51e-05	0.000947	CbGpPWpGaD
Methadone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	5.5e-05	0.000946	CbGpPWpGaD
Methadone—ABCB1—Allograft Rejection—TNF—Crohn's disease	5.41e-05	0.000929	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—FADS1—Crohn's disease	5.35e-05	0.00092	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—RASGRP1—Crohn's disease	5.33e-05	0.000916	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CCR6—Crohn's disease	5.32e-05	0.000914	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—FADS1—Crohn's disease	5.23e-05	0.000899	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—IL2RA—Crohn's disease	5.21e-05	0.000895	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—MTMR3—Crohn's disease	5.08e-05	0.000873	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PLA2G4F—Crohn's disease	5.06e-05	0.000869	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GPX4—Crohn's disease	5.01e-05	0.000861	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL3—Crohn's disease	5.01e-05	0.00086	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—SLC11A1—Crohn's disease	4.98e-05	0.000856	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—MTMR3—Crohn's disease	4.97e-05	0.000853	CbGpPWpGaD
Methadone—OPRK1—GPCR ligand binding—CXCL8—Crohn's disease	4.96e-05	0.000852	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—GPX4—Crohn's disease	4.9e-05	0.000842	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—RASGRP1—Crohn's disease	4.84e-05	0.000832	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—GCKR—Crohn's disease	4.84e-05	0.000832	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RBX1—Crohn's disease	4.81e-05	0.000827	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL2RA—Crohn's disease	4.73e-05	0.000813	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—PTGER4—Crohn's disease	4.68e-05	0.000805	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CCR6—Crohn's disease	4.67e-05	0.000802	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—IL2RA—Crohn's disease	4.57e-05	0.000785	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PLA2G4F—Crohn's disease	4.51e-05	0.000776	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PLA2G4F—Crohn's disease	4.41e-05	0.000757	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—MTMR3—Crohn's disease	4.3e-05	0.000739	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RBX1—Crohn's disease	4.22e-05	0.000725	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—UBE2D1—Crohn's disease	4.22e-05	0.000725	CbGpPWpGaD
Methadone—OPRM1—GPCR ligand binding—CXCL8—Crohn's disease	4.19e-05	0.00072	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	4.15e-05	0.000714	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL2RA—Crohn's disease	4.15e-05	0.000713	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PLA2G4F—Crohn's disease	4.12e-05	0.000707	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—PTGER4—Crohn's disease	4.11e-05	0.000706	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RIPK2—Crohn's disease	4.09e-05	0.000703	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL3—Crohn's disease	3.99e-05	0.000686	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	3.98e-05	0.000684	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—FADS1—Crohn's disease	3.96e-05	0.00068	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—Crohn's disease	3.95e-05	0.000679	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CCR6—Crohn's disease	3.94e-05	0.000678	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—FADS1—Crohn's disease	3.87e-05	0.000665	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—IL2RA—Crohn's disease	3.86e-05	0.000664	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—RASGRP1—Crohn's disease	3.86e-05	0.000663	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—MTMR3—Crohn's disease	3.84e-05	0.00066	CbGpPWpGaD
Methadone—ABCB1—Metabolism—MTMR3—Crohn's disease	3.75e-05	0.000644	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GPX4—Crohn's disease	3.71e-05	0.000637	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—UBE2D1—Crohn's disease	3.7e-05	0.000636	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GPX4—Crohn's disease	3.62e-05	0.000622	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RIPK2—Crohn's disease	3.59e-05	0.000617	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—GCKR—Crohn's disease	3.58e-05	0.000615	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RBX1—Crohn's disease	3.57e-05	0.000613	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—MTMR3—Crohn's disease	3.53e-05	0.000607	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PLA2G4F—Crohn's disease	3.52e-05	0.000605	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL2RA—Crohn's disease	3.51e-05	0.000603	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—JAK2—Crohn's disease	3.5e-05	0.000602	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—MTMR3—Crohn's disease	3.5e-05	0.000602	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL3—Crohn's disease	3.5e-05	0.000601	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—GCKR—Crohn's disease	3.5e-05	0.000601	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SOCS1—Crohn's disease	3.5e-05	0.000601	CbGpPWpGaD
Methadone—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.48e-05	0.000599	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—PTGER4—Crohn's disease	3.47e-05	0.000597	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—RASGRP1—Crohn's disease	3.38e-05	0.000582	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—FADS1—Crohn's disease	3.35e-05	0.000576	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—TYK2—Crohn's disease	3.33e-05	0.000573	CbGpPWpGaD
Methadone—OPRD1—GPCR downstream signaling—CXCL8—Crohn's disease	3.2e-05	0.000549	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—JAK2—Crohn's disease	3.18e-05	0.000547	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GPX4—Crohn's disease	3.14e-05	0.000539	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—UBE2D1—Crohn's disease	3.13e-05	0.000537	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—JAK2—Crohn's disease	3.07e-05	0.000528	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SOCS1—Crohn's disease	3.07e-05	0.000527	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RIPK2—Crohn's disease	3.03e-05	0.000521	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—GCKR—Crohn's disease	3.03e-05	0.000521	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—SMAD3—Crohn's disease	3.02e-05	0.000519	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—MTMR3—Crohn's disease	2.99e-05	0.000514	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—FADS1—Crohn's disease	2.99e-05	0.000514	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL3—Crohn's disease	2.96e-05	0.000508	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—TYK2—Crohn's disease	2.92e-05	0.000502	CbGpPWpGaD
Methadone—ABCB1—Metabolism—FADS1—Crohn's disease	2.92e-05	0.000502	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—CXCL8—Crohn's disease	2.9e-05	0.000499	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—RASGRP1—Crohn's disease	2.86e-05	0.000491	CbGpPWpGaD
Methadone—OPRK1—GPCR downstream signaling—CXCL8—Crohn's disease	2.8e-05	0.000482	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GPX4—Crohn's disease	2.8e-05	0.000481	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL2RA—Crohn's disease	2.79e-05	0.00048	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—JAK2—Crohn's disease	2.79e-05	0.000479	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—FADS1—Crohn's disease	2.75e-05	0.000473	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GPX4—Crohn's disease	2.73e-05	0.00047	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—FADS1—Crohn's disease	2.73e-05	0.000469	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	2.71e-05	0.000467	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—GCKR—Crohn's disease	2.7e-05	0.000465	CbGpPWpGaD
Methadone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Crohn's disease	2.67e-05	0.000459	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—SMAD3—Crohn's disease	2.65e-05	0.000455	CbGpPWpGaD
Methadone—ABCB1—Metabolism—GCKR—Crohn's disease	2.64e-05	0.000454	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—JAK2—Crohn's disease	2.6e-05	0.000446	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SOCS1—Crohn's disease	2.59e-05	0.000445	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GPX4—Crohn's disease	2.58e-05	0.000443	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GPX4—Crohn's disease	2.55e-05	0.000439	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—CXCL8—Crohn's disease	2.54e-05	0.000437	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—GCKR—Crohn's disease	2.49e-05	0.000428	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—TYK2—Crohn's disease	2.47e-05	0.000425	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—GCKR—Crohn's disease	2.47e-05	0.000424	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL2RA—Crohn's disease	2.45e-05	0.000421	CbGpPWpGaD
Methadone—OPRM1—GPCR downstream signaling—CXCL8—Crohn's disease	2.37e-05	0.000407	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—JAK2—Crohn's disease	2.36e-05	0.000405	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—FADS1—Crohn's disease	2.33e-05	0.0004	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—ALB—Crohn's disease	2.32e-05	0.000398	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—MTMR3—Crohn's disease	2.31e-05	0.000397	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—SMAD3—Crohn's disease	2.24e-05	0.000384	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GPX4—Crohn's disease	2.18e-05	0.000375	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	2.17e-05	0.000372	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—CXCL8—Crohn's disease	2.15e-05	0.00037	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—GCKR—Crohn's disease	2.11e-05	0.000362	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL2RA—Crohn's disease	2.07e-05	0.000356	CbGpPWpGaD
Methadone—CYP2C18—Metabolism—PTGS2—Crohn's disease	2.03e-05	0.000348	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—TYK2—Crohn's disease	1.97e-05	0.000338	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.93e-05	0.000332	CbGpPWpGaD
Methadone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.89e-05	0.000326	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—JAK2—Crohn's disease	1.88e-05	0.000323	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—FADS1—Crohn's disease	1.8e-05	0.000309	CbGpPWpGaD
Methadone—ABCB1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.79e-05	0.000308	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—ALB—Crohn's disease	1.77e-05	0.000305	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.76e-05	0.000303	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—TYK2—Crohn's disease	1.73e-05	0.000297	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—CXCL8—Crohn's disease	1.71e-05	0.000295	CbGpPWpGaD
Methadone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.69e-05	0.000291	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GPX4—Crohn's disease	1.68e-05	0.000289	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—JAK2—Crohn's disease	1.65e-05	0.000283	CbGpPWpGaD
Methadone—OPRD1—Signaling by GPCR—IL6—Crohn's disease	1.63e-05	0.00028	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—GCKR—Crohn's disease	1.63e-05	0.00028	CbGpPWpGaD
Methadone—CYP19A1—Metabolism—PTGS2—Crohn's disease	1.55e-05	0.000267	CbGpPWpGaD
Methadone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.54e-05	0.000265	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—ALB—Crohn's disease	1.54e-05	0.000265	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—Crohn's disease	1.51e-05	0.000259	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—CXCL8—Crohn's disease	1.5e-05	0.000258	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—TYK2—Crohn's disease	1.46e-05	0.000251	CbGpPWpGaD
Methadone—OPRK1—Signaling by GPCR—IL6—Crohn's disease	1.43e-05	0.000246	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—JAK2—Crohn's disease	1.39e-05	0.000239	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—STAT3—Crohn's disease	1.38e-05	0.000237	CbGpPWpGaD
Methadone—CYP3A7—Metabolism—PTGS2—Crohn's disease	1.35e-05	0.000232	CbGpPWpGaD
Methadone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	1.32e-05	0.000226	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—CXCL8—Crohn's disease	1.27e-05	0.000218	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—STAT3—Crohn's disease	1.21e-05	0.000208	CbGpPWpGaD
Methadone—OPRM1—Signaling by GPCR—IL6—Crohn's disease	1.21e-05	0.000208	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—ALB—Crohn's disease	1.14e-05	0.000196	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—ALB—Crohn's disease	1.11e-05	0.000191	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—STAT3—Crohn's disease	1.02e-05	0.000176	CbGpPWpGaD
Methadone—CYP2B6—Metabolism—PTGS2—Crohn's disease	9.97e-06	0.000171	CbGpPWpGaD
Methadone—CYP3A5—Metabolism—PTGS2—Crohn's disease	9.74e-06	0.000167	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—ALB—Crohn's disease	9.64e-06	0.000166	CbGpPWpGaD
Methadone—OPRD1—Signaling Pathways—IL6—Crohn's disease	9.63e-06	0.000166	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—ALB—Crohn's disease	8.61e-06	0.000148	CbGpPWpGaD
Methadone—OPRK1—Signaling Pathways—IL6—Crohn's disease	8.45e-06	0.000145	CbGpPWpGaD
Methadone—CYP2C8—Metabolism—PTGS2—Crohn's disease	8.44e-06	0.000145	CbGpPWpGaD
Methadone—ABCB1—Metabolism—ALB—Crohn's disease	8.4e-06	0.000144	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—ALB—Crohn's disease	7.92e-06	0.000136	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—ALB—Crohn's disease	7.85e-06	0.000135	CbGpPWpGaD
Methadone—CYP2C19—Metabolism—PTGS2—Crohn's disease	7.53e-06	0.000129	CbGpPWpGaD
Methadone—ABCB1—Metabolism—PTGS2—Crohn's disease	7.35e-06	0.000126	CbGpPWpGaD
Methadone—OPRM1—Signaling Pathways—IL6—Crohn's disease	7.14e-06	0.000123	CbGpPWpGaD
Methadone—CYP2D6—Metabolism—PTGS2—Crohn's disease	6.93e-06	0.000119	CbGpPWpGaD
Methadone—CYP2C9—Metabolism—PTGS2—Crohn's disease	6.87e-06	0.000118	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—ALB—Crohn's disease	6.71e-06	0.000115	CbGpPWpGaD
Methadone—CYP1A2—Metabolism—PTGS2—Crohn's disease	5.87e-06	0.000101	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—ALB—Crohn's disease	5.18e-06	8.9e-05	CbGpPWpGaD
Methadone—CYP3A4—Metabolism—PTGS2—Crohn's disease	4.53e-06	7.78e-05	CbGpPWpGaD
